Community/Retail

In 2014, the drug was granted accelerated approval to treat patients with ALK-positive NSCLC whose disease progressed on or who are intolerant to crizotinib.

The FDA today approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder.

At the Pharmacy Quality Alliance annual meeting in Baltimore, Maryland, Eleanor Perfetto, PhD, MS, Senior Vice President for Strategic Initiatives at the National Health Council, spoke with Pharmacy Times about how health systems are taking a more patient-centered approach.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.